Welcome to our dedicated page for FATE THERAPEUTICS SEC filings (Ticker: FATE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on FATE THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into FATE THERAPEUTICS's regulatory disclosures and financial reporting.
Fate Therapeutics President and CEO Bahram Valamehr reported an automatic sale of 28,946 shares of Common Stock. The shares were sold on open market on May 20, 2026 at a weighted average price of $1.8822 per share to cover tax withholding obligations tied to the vesting of 50,000 performance-based RSUs granted on July 29, 2024. The transactions were executed pursuant to a prior irrevocable sell-to-cover election and were not made at his discretion. Following these sales, Valamehr continues to hold 635,762 shares directly.
Fate Therapeutics reported a Q1 2026 net loss of $31.2 million, improving from a $37.6 million loss a year earlier, as it continued investing in its off-the-shelf iPSC-derived cell therapy pipeline. Collaboration revenue was $1.3 million compared with $1.6 million in Q1 2025, all from research and preclinical services under its Ono partnership.
Research and development expenses were $24.7 million versus $29.1 million, and general and administrative expenses were $9.6 million versus $13.8 million, reflecting ongoing cost reductions. Cash, cash equivalents and short‑term investments totaled $174.8 million as of March 31, 2026, and management believes this will fund operations for at least twelve months. The company remains a clinical‑stage biopharmaceutical business with an accumulated deficit of about $1.6 billion and no product sales to date.
Fate Therapeutics reported first quarter 2026 results and highlighted major advances in its iPSC-derived cell therapy pipeline. Collaboration revenue was $1.3 million, while total operating expenses fell to $34.3 million, about a 20% year-over-year reduction, leading to a narrower net loss of $31.2 million (or $0.26 per share). The company ended March 31, 2026 with $174.8 million in cash, cash equivalents and investments, which it expects to fund operations into 2028.
Clinically, FT819, an off-the-shelf CD19 CAR T-cell for autoimmune disease, advanced with FDA selection into the CMC Development and Readiness Pilot program and continued enrollment in a Phase 1 trial across multiple autoimmune indications. A Phase 2 potentially registrational lupus nephritis study of FT819 is planned to start dosing in the second half of 2026. Next-generation programs FT839 and FT836 also progressed, with FT839 nearing IND submission for a Phase 1 autoimmune basket trial and FT836 showing early safety in a Phase 1 solid tumor study.
Fate Therapeutics officer Cindy Tahl exercised stock options to acquire a total of 166,664 shares of common stock on May 6, 2026. She exercised 44,444 options at $1.05 per share and 122,220 options at $1.32 per share, with no open-market sales reported. Following these transactions, she directly holds 653,745 shares of common stock. The options exercised relate to grants that vest in 36 equal monthly installments starting January 1, 2025 and January 1, 2026, becoming fully vested in 2028 and 2029, subject to her continued service.
Fate Therapeutics director Robert S. Epstein exercised stock options to acquire 25,000 shares of Common Stock at $1.69 per share. The options related to shares that vested on the date of the company’s 2017 Annual Meeting of Stockholders. After the transaction, he directly holds 36,331 Fate Therapeutics shares.
FATE Therapeutics director William H. Rastetter exercised stock options to acquire 25,000 shares of Common Stock at $1.69 per share. Following the exercise, he holds 36,331 Common shares directly. In addition, 459,272 shares are held indirectly by The Investment 2002 Trust and 146,821 shares are held indirectly by The Rastetter Family Trust, where he serves in trustee roles.
Fate Therapeutics, Inc. is asking stockholders to vote at its June 12, 2026 annual meeting on four key items: electing three Class I directors, ratifying Ernst & Young LLP as auditor, approving a non-binding Say-on-Pay proposal, and expanding its equity plan.
The board seeks approval to amend and restate the 2022 Stock Option and Incentive Plan to add 7,000,000 shares, increasing the reserve from 24,500,000 to 31,500,000 shares, an amount described as 6.0% of shares outstanding as of March 31, 2026. The proxy also details board independence, committee structure, director compensation (including higher cash retainers and larger option grants), voting mechanics such as broker non-votes, and procedures and deadlines for future stockholder proposals and director nominations.